📢 Cellino is proud to announce the publication of this collaborative white paper on considerations for the development of iPSC-derived cell therapies in Cytotherapy! Co-authored by Marinna Madrid, PhD, our Co-Founder & Chief Product Officer, Bar Makovoz, PhD, our Principal Product Manager, and the The Japanese Society for Regenerative Medicine (JSRM)-ISCT iPSC Committee, this piece focuses on critical considerations for scaling iPSC production. iPSC-derived cell therapies hold immense promise for patients by treating and potentially curing a wide range of chronic degenerative conditions. Scaling up these therapies involves overcoming challenges such as complex manufacturing processes, meticulous QA measures, high production costs, and a patchwork of regulatory standards. This white paper explores these key topics and more: 🔹 Overview of required elements for developing autologous and allogeneic iPSC-derived cell therapies 🔹 Global regulatory guidance and development of iPSC-derived cell therapies across the US, UK, Japan, Australia, and the EU 🔹 Challenges to widespread adoption and opportunities to automate cell therapy manufacturing to expand patient access 📰 Learn more about the Committee’s findings at https://lnkd.in/grHmxF84 Reinforcing our commitment to continuous innovation, this work focuses on strategies to make these transformative treatments more accessible. We extend our appreciation to ISCT, International Society for Cell & Gene Therapy, Uma Lakshmipathy, Xiaokui Zhang, Kapil Bharti, Dominic Wall, Yoji Sato, George Muschler, Anthony Ting, Nathan Smith, Shuhei Deguchi, Shin Kawamata, Jen Moore, Stephen Sullivan, Arwa Z. Al-Riyami, Veronica Falco
Cellino
Biotechnology Research
Cambridge, Massachusetts 14,416 followers
Your Cells, Your Cure™
About us
Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.
- Website
-
http://www.cellinobio.com
External link for Cellino
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Founded
- 2017
Locations
-
Primary
Get directions
750 Main Street
Cambridge, Massachusetts 02139, US
Employees at Cellino
Updates
-
We are excited to share that Nabiha Saklayen, our CEO & Co-Founder, will be speaking at Decoding Bio’s AI x Bio Summit in #NYC on July 25. This summit, held at the NYSE, brings together pharma executives, founders, researchers, and investors to engage in deep conversations about the challenges and opportunities within the #AI & #biotech ecosystem. Nabiha will be speaking on a panel on "Lessons from Building in Biotech" moderated by Bigyan Bista of Enveda Biosciences. She will discuss strategies for navigating growth, innovation, and sustainability in the biotech industry. Joining fellow panelists including Michael Nally of Generate:Biomedicines and Sajith Wickramasekara of Benchling, they’ll explore building strategies to keep up with the evolving tech stack. We look forward to contributing to the conversations that will shape the future of biotech! 🚀 🌐 #CellinoBio #Biotechnology #Innovation #Collaboration #Biomanufacturing #ArtificialIntelligence #MachineLearning #PersonalizedMedicine #Therapeutics #RegenMed #YourCellsYourCure
-
-
👏 A big thank you to the Alliance for Regenerative Medicine for hosting Willie T. Reaves, our Head of Public Engagement, at today's U.S. Policy & Advocacy Forum during the Cell & Gene Congressional Fly-In (#CGFlyIn24) in Washington, DC. Willie shared his insights on "Building an Autonomous Biomanufacturing Technology to Scale Personalized Regenerative Medicine." He did a deep dive on Cellino’s use of artificial intelligence to significantly improve the #biomanufacturing process for personalized regenerative medicines and expand access to transformative therapies for patients. Thank you to Miranda Franco and Jordan LaCrosse for providing policy perspectives, Stephanie Heathman (Bhamdeo) from the Opie Jones Foundation, Daria F. and Jennifer Cana from Advanced Research Projects Agency for Health (ARPA-H), and Dr. Nicole Verdun from the FDA for making the discussions so impactful. #CellinoBio #AllianceRM #Policy #Innovation #RegenMed #Biotech #Collaboration #Healthcare #Autologous #AI #MachineLearning #PersonalizedMedicine #YourCellsYourCure
Head of Public Engagement at Cellino | Business Strategy & Public Affairs Executive | Former Chief Business Strategy Officer at BIO
I’m thrilled to be in DC for the Alliance for Regenerative Medicine Cell & Gene Congressional Fly-In! We kicked off the day with the U.S. Policy & Advocacy Forum, where I will presented on Cellino’s technology for scaling up personalized regenerative medicines. 📌It was great to hear policy perspectives on AI from Miranda Franco and Jordan LaCrosse, who gave a great overview of AI-related topics that lawmakers are hoping to learn about. From the House AI Task Force to the Senate AI Working Group and numerous other initiatives, our members of Congress are curious to learn more about these emerging technologies and it's important to provide education in these areas! 📌Many thanks to Stephanie Heathman (Bhamdeo) of the Opie Jones Foundation, who shared the story of then 5-month old Opie, who was diagnosed with acute lymphoblastic leukemia and ultimately was treated (and cured—he is still cancer-free and turns 4 this week!) with a CAR-T therapy. This was a poignant reminder that everything we do is for patients. 📌It was a pleasure to introduce Daria F. and Jennifer Cana of the Advanced Research Projects Agency for Health (ARPA-H), who shared ARPA-H's latest initiatives and gave us an overview of the agency's program to engineer immune cells inside the body. 📌I loved hearing from Dr. Nicole Verdun of the FDA, who described an exciting new Cell & Gene Therapy Interactive Site Tours Program designed to give CBER reviewers the opportunity to our biomanufacturing facilities! We're not even finished with the day yet and have a packed agenda tomorrow of meetings with the offices of House and Senate members to advocate for policies that support the development of cell & gene therapies, as well as expanded patient access to these novel modalities! It may be 102 degrees in DC tomorrow, but the weather isn't the only thing that's hot—regenerative medicine is on fire! Let's go!! 🚀 🚀🚀 #regenerativemedicine #celltherapies #biomanufacturing #policy #equity #patientaccess
-
-
We are pleased to announce that Justin Birtz has joined Cellino as SVP, People & Culture. Justin brings diverse experience spanning biotech/pharma, med device, healthcare tech, robotics, automation, and cybersecurity. He specializes in helping growth-stage tech companies navigate rapid expansion and transformation. Justin comes to us from Lyra Therapeutics, where he led efforts to develop, scale, and mature the organization for commercialization, impacting the lives of millions of patients. His expertise in strategic development and commercialization will support our mission of pioneering automated biomanufacturing solutions for personalized regenerative medicines. Welcome aboard, Justin! We look forward to achieving incredible milestones together. 🚀 #CellinoBio #EmployeeSpotlight #Biotech #LifeSciences #Innovation #STEMCareers #BioManufacturing #PersonalizedMedicine #RegenMed #WelcomeToCellino
-
-
👏 We are excited to welcome Mahder Haile to Cellino as a Bioprocess Operations Senior Associate! Mahder joins us from Garuda Therapeutics, where he played a key role in scaling up iPSC expansion and EB differentiation utilizing bioreactors. He also has experience in GMP manufacturing, working with closed system technologies to develop cell therapy products. We look forward to Mahder's contributions as we continue to advance biomanufacturing for personalized regenerative medicines. Welcome aboard, Mahder! #CellinoBio #Biotech #Innovation #STEMCareers #EmployeeSpotlight #RegenMed #PersonalizedMedicine #Biomanufacturing #YourCellsYourCure #WelcomeToCellino
-
-
🔬 The U.S. Policy & Advocacy Forum during Alliance for Regenerative Medicine's (ARM) Cell & Gene Congressional Fly-In begins next week, and we're excited to have Willie T. Reaves, Head of Public Engagement, and Marinna Madrid, PhD, Co-Founder & Chief Product Officer, representing Cellino in Washington, DC. Willie will speak on "Building an Autonomous Biomanufacturing Technology to Scale Personalized Regenerative Medicine," showcasing our innovative #biomanufacturing platform. We’re looking forward to his session from 10 AM to 12 PM EDT on Monday, July 15. Marinna will also be present to connect with colleagues and discuss the challenges and progress in making personalized regenerative medicine more accessible to patients. Follow Cellino for updates from the Fly-In! 🚀 #CellinoBio #AllianceRM #Policy #RegenMed #Biotech #Collaboration #Innovation #Healthcare #Autologous #AI #MachineLearning #PersonalizedMedicine #YourCellsYourCure
-
-
👏 Join us in welcoming Jeffrey Yao, Bioprocess Operations Senior Associate at Cellino! Jeffrey's experience spans from working at Clade Therapeutics (acquired by Century Therapeutics), where he was part of the Process Development team focusing on iPSC-to-T cell differentiation and scale-up. He was previously at Editas Medicine, where he focused on iPSCs to NK cells. His expertise will contribute to advancing our biomanufacturing platform for personalized regenerative medicines. We are excited to work with Jeffrey and explore automation and manufacturing solutions together! #CellinoBio #Biotech #Innovation #STEMCareers #EmployeeSpotlight #RegenMed #PersonalizedMedicine #Biomanufacturing #YourCellsYourCure #WelcomeToCellino
-
-
🚀 Are you attending #ISSCR2024 this week? We’re excited that Marinna Madrid, PhD, Co-Founder & Chief Product Officer, and Rebecca "Becky" Kusko, PhD, Chief of Staff & Head of Strategy at Cellino, will be in attendance from July 10-13, 2024! Marinna and Rebecca are looking forward to the great lineup of presentations and discussions planned for this year's International Society for Stem Cell Research (#ISSCR2024). Be sure to connect with them to hear more about Cellino’s latest innovations in #regenerativemedicine, including our approach to scalable #biomanufacturing for personalized cell therapies. 🤝 We’re looking forward to connecting with you in #Hamburg! See the program agenda here: https://bit.ly/45Lg7YS #CellinoBio #StemLeaders #Biotech #BiotechInnovation #Collaboration #Therapeutics #ResearchAndDevelopment #PersonalizedMedicine #RegenMed #YourCellsYourCure #Conference #ISSCR
-
-
🗓️ Mark your calendars! We're excited to share that our team members, Marinna Madrid, PhD, Co-Founder & Chief Product Officer, and Rebecca "Becky" Kusko, PhD, Chief of Staff & Head of Strategy at Cellino, will be attending the International Society for Stem Cell Research (#ISSCR2024) Annual Meeting in Hamburg, Germany from July 10-13, 2024! Marinna is an ISSCR Committee Member and part of the Program Leadership, and she and Rebecca are looking forward to connecting with colleagues and discussing the future of stem cell research and emerging technologies. If you're attending, be sure to connect with them to learn how Cellino’s autonomous #biomanufacturing platform is advancing personalized #regenerativemedicine and its potential to accelerate the development of transformational therapies for patients. 🤝 Come meet us in #Hamburg and stay tuned for the latest updates from the conference! Explore the program agenda here: https://bit.ly/45Lg7YS #CellinoBio #StemLeaders #Biotech #BiotechInnovation #Collaboration #Therapeutics #ResearchAndDevelopment #PersonalizedMedicine #RegenMed #YourCellsYourCure #Conference #ISSCR
-
🔬 As the transformative potential of personalized regenerative medicine continues to evolve, Cellino is proud to announce that Willie T. Reaves, our Head of Public Engagement, and Marinna Madrid, PhD, our Co-Founder & Chief Product Officer, will represent Cellino in Washington, DC, for the U.S. Policy & Advocacy Forum during the Alliance for Regenerative Medicine's (ARM) Cell & Gene Congressional Fly-In next month. Willie will be speaking on "Real World Applications of AI in Regenerative Medicine," showcasing how our autonomous #biomanufacturing platform leverages machine learning and automation to scale up personalized regenerative medicines. This session will take place on July 15 from 10 AM to 12 PM EDT. Marinna will participate in discussions about the challenges and advancements in regenerative medicine, in efforts to make these important treatments accessible to all patients in need. Key highlights include an update from ARM’s Government Affairs team on strategic objectives, a preview of ARM's "Cell and Gene Therapy Framework," and a discussion on the role of AI in CGT administration with real-world examples. We’re excited to join industry colleagues to address the challenges and unlock new opportunities in regenerative medicine. Stay tuned for updates from the Fly-In by following Cellino and our team members! 🚀 #CellinoBio #AllianceRM #Policy #RegenMed #Biotech #Collaboration #Innovation #Healthcare #Biomanufacturing #Autologous #ArtificialIntelligence #AI #MachineLearning #PersonalizedMedicine #YourCellsYourCure
-